alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit








Exhibit 10.2






 
December 18, 2016


Dear Mr. Maslowski,


This letter will confirm your appointment to serve as the Chief Executive Officer (“CEO”) of Fibrocell Science, Inc. (the “Company”) and a member of the Board of Directors of the Company (the “Board”), in each case effective as of December 16, 2016 (the “Effective Date”).  In your role as CEO, you will have all of the duties, responsibilities and authority commensurate with such position.  You agree that you will immediately resign from the Board if and when you are no longer serving as the CEO of the Company. 


Commencing on the Effective Date, you will receive a base salary of $350,000 per annum.  You will be eligible to earn an annual performance bonus, subject to the attainment of annual performance goals as determined by the Board (or a committee thereof).  Your target annual bonus starting in fiscal year 2017 will be 50% of your base salary.  You were granted an option on the Effective Date (the “Option”) to purchase 250,000 shares of the Company’s common stock under the Company’s 2009 Equity Incentive Plan (the “2009 Plan”).  The exercise price of the Option is $0.6625 per share.  Of the shares underlying the Option, 62,500 shares will vest and become exercisable on the first anniversary of the grant date, and the remaining 187,500 shares underlying the Option will vest and become exercisable in equal quarterly installments thereafter, subject to your continued employment with the Company through the applicable vesting date. The Option will be subject to the terms and conditions of the 2009 Plan and the award agreement issued to you thereunder.  You will be eligible to participate in and be covered on the same basis as other senior management of the Company under all employee benefit plans and programs maintained by the Company, and you will be eligible to receive four weeks of vacation annually.  You will be reimbursed for your reasonable business related expenses in accordance with the Company’s standard policies and practices as in effect from time to time.


The nature of your employment relationship is at-will. Accordingly, either you or the Company may terminate your employment at any time and for any or no reason, subject to the terms and conditions of this letter.  This letter amends your Employment Agreement with the Company, dated September 14, 2015 (the “Employment Agreement”).  Except as expressly herein amended, the Employment Agreement remains in full force and effect.  This letter may not be terminated or modified orally.




























1







Please return to me a signed copy of this letter as acknowledgment of your agreement to this arrangement.


Sincerely,


Fibrocell Science, Inc.


	
	
	/s/ Michael F. Marino

	Michael F. Marino

	Senior Vice President, General Counsel and Corporate Secretary






                
	
	
	/s/ John M. Maslowski

	John M. Maslowski










2
2

 .
Exhibit 11.1
                                                            
                        GENERAL NUTRITION COMPANIES, INC. AND SUBSIDIARIES
                           Computation of Net Earnings (Loss) Per Share
                                                                
                                                                
                              12 Weeks Ended             36 Weeks Ended
                         October 11,   October 12,  October 11,  October 12,
                            1997           1996         1997        1996
                               (in thousands except per share amounts)
                                                                
Net earnings (loss)      $ 23,932      $ 17,870      $ 70,845   $ (13,831)
 available for common
 shares
                                                                
Common stock               81,040        82,853        80,896      86,364
Outstanding stock options   2,200         1,717         2,028           -
Primary weighted average
 common shares             83,240        84,570        82,924      86,364
                                                                
Common stock               81,040        82,853        80,896      86,364
Outstanding stock options   2,305         2,144         2,305           -
Fully diluted weighted
 average common shares     83,345        84,997        83,201      86,364
  
                                                          
Primary earnings (loss)
  per share               $  0.29        $ 0.21        $ 0.85      $(0.16)
                                                                
Fully diluted earnings
  (loss) per share        $  0.29        $ 0.21        $ 0.85      $(0.16)
USDA APHIS Tribal Nations Wild Cervid 

Chronic Wasting Disease Opportunities 

2022 Cooperative Agreements

2022 Spending Plan

October 2022
2022 Spending Plans for the Tribal Nations Wild Cervid Chronic Wasting

Disease Opportunities 2022 Cooperative Agreements

USDA APHIS WS is awarding $274,973 through Cooperative Agreements to five Federally recognized 

Native American Tribal governments to combat CWD on Tribal lands across five different states. During 

the 2022 competitive wild cervid CWD funding process not enough proposals were received to utilize all 

available funds. Two additional cooperative agreements were set up, awarding $250,700 for wild cervid 

CWD surveillance on Tribal lands. These projects will allow recipients to further develop and implement 

CWD management, response, and research activities in wild cervids, including surveillance and testing. 

Funded projects are listed below.

Tribal Wild Cervid Management Projects

Project Title Entity Funding Amount

Seneca Nation of Indians CWD Education 

Awareness and Monitoring Program Seneca Nation of Indians $75,000.00

Development of CWD Management Plan and 

Monitoring on the Coeur d’Alene Reservation Coeur d’Alene Tribe $26,672.00

Chronic Wasting Disease Surveillance on the 

Flathead Indian Reservation, 2022

Confederated Salish and 

Kootenai Tribes $64,795.00

Spokane Tribe Chronic Wasting Disease Outreach 

and Surveillance Project Spokane Tribe of Indians $33,506.81

Blackfeet CWD Observation/Monitoring

Blackfeet Tribe of the 

Blackfeet Indian 

Reservation $75,000.00

SUBTOTAL $274,973.81

FY2022 CWD Tribal Collaboration, CWD 

Surveillance

Oklahoma Tribal Conservation 

Advisory $145,100.00

CWD Diagnostic Services, Tribes

Colorado State University 

Veterinary Diagnostic 

Laboratory $105,600.00

SUBTOTAL $250,700.00

TOTAL $525,673.81
# C_2019187EN.01007801.xml

| 3.6.2019 | EN | Official Journal of the European Union | C 187/78 |
| --- | --- | --- | --- |

3.6.2019

EN

Official Journal of the European Union

C 187/78

---

Judgment of the General Court of 11 April 2019 — Užstato sistemos administratorius v EUIPO — DPG Deutsche Pfandsystem (Representation of a bottle with an arrow)

(Case T-477/18) (1)

(EU trade mark - Opposition proceedings - Application for an EU figurative mark representing a bottle and an arrow - Earlier EU figurative mark representing a can, a bottle and an arrow - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EU) 2017/1001)

(2019/C 187/84)

Language of the case: English

Parties

Applicant: Užstato sistemos administratorius VŠĮ (Vilnius, Lithuania) (represented by: I. Lukauskienė, lawyer)

Defendant: European Union Intellectual Property Office (represented by: P. Sipos and H. O’Neill, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO: DPG Deutsche Pfandsystem GmbH (Berlin, Germany)

Re:

Action brought against the decision of the Second Board of Appeal of EUIPO of 22 May 2018 (Case R 2203/2017-2), relating to opposition proceedings between DPG Deutsche Pfandsystem and Užstato sistemos administratorius.

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Užstato sistemos administratorius VšĮ to pay the costs. |
| --- | --- |

2.

Orders Užstato sistemos administratorius VšĮ to pay the costs.

---

(1)  OJ C 341, 24.9.2018.

---
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 17-6691

UNITED STATES OF AMERICA,

 Plaintiff - Appellee,

v.

MALCOLM DEMON TYLER, a/k/a Milt,

 Defendant - Appellant.

Appeal from the United States District Court for the Northern District of West Virginia, 

at Wheeling. Frederick P. Stamp, Jr., Senior District Judge. (5:13-cr-00009-FPS-JES-2; 

5:16-cv-00094-FPS-JES)

Submitted: October 31, 2017 Decided: December 4, 2017

Before KEENAN, WYNN, and DIAZ, Circuit Judges.

Dismissed and remanded by unpublished per curiam opinion.

Malcolm Demon Tyler, Appellant Pro Se. Randolph John Bernard, OFFICE OF THE 

UNITED STATES ATTORNEY, Wheeling, West Virginia, for Appellee.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Malcolm Demon Tyler seeks to appeal the district court’s order denying relief on 

his 28 U.S.C. § 2255 (2012) motion. Before addressing the merits of Tyler’s appeal, we

must first be assured that we have jurisdiction. Porter v. Zook, 803 F.3d 694, 696 (4th 

Cir. 2015). We may exercise jurisdiction only over final orders, 28 U.S.C. § 1291 

(2012), and certain interlocutory and collateral orders, 28 U.S.C. § 1292 (2012); Fed. R. 

Civ. P. 54(b); Cohen v. Beneficial Indus. Loan Corp., 337 U.S. 541, 545-47 (1949). 

“Ordinarily, a district court order is not final until it has resolved all claims as to all 

parties.” Porter, 803 F.3d at 696 (internal quotation marks omitted); see Fed. R. Civ. P. 

54(b). Generally, “a final decision is one that ends the litigation on the merits and leaves 

nothing for the court to do but execute the judgment.” Ray Haluch Gravel Co. v. Cent. 

Pension Fund of Int’l Union of Operating Eng’rs & Participating Emp’rs, 134 S. Ct. 773, 

779 (2014) (internal quotation marks omitted). “Regardless of the label given a district 

court decision, if it appears from the record that the district court has not adjudicated all 

of the issues in a case, then there is no final order.” Porter, 803 F.3d at 696.

Tyler initially challenged his career offender designation based on Johnson v. 

United States, 135 S. Ct. 2551 (2015), pursuant to this court’s authorization to file a 

successive § 2255 motion. Subsequently, Tyler was granted leave to supplement his 

habeas motion, and Tyler filed a supplement raising claims based on Mathis v. United 

States, 136 S. Ct. 2243 (2016). Because the district court did not resolve the Mathis

claims raised in Tyler’s supplement, we lack jurisdiction over this appeal. See Porter, 

803 F.3d at 695, 699.
3

 Accordingly, we dismiss the appeal as interlocutory and remand to the district 

court for consideration of Tyler’s Mathis claims. We express no opinion regarding the 

merits of Tyler’s claims. We dispense with oral argument because the facts and legal 

contentions are adequately presented in the materials before this court and argument 

would not aid the decisional process.

DISMISSED AND REMANDED
27845

#### State v. Amina

Affirmed
#### Parikh v. State

14832

10/17/91

Denied
19529

#### State v. Kaihewalu

Affirmed
Exhibit 99.1



CERTIFICATIONS PURSUANT TO 18 U.S.C.
SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report on Form 10-Q of Education Management Corporation (the Company) for the period ended
December 31, 2002 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Robert B. Knutson, Chairman and Chief Executive Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



(1). The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and



(2). The information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.



Date:
February 7, 2003

/S/   ROBERT B. KNUTSONRobert B. KnutsonChairman and Chief Executive Officer




In
connection with the Quarterly Report on Form 10-Q of Education Management Corporation (the Company) for the period ended December 31, 2002 as filed with the Securities and Exchange Commission on the date hereof (the Report),
I, Robert T. McDowell, Executive Vice President and Chief Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



(1). The Report fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and



(2). The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: February 7, 2003



/S/   ROBERT T. MCDOWELLRobert T. McDowellExecutive Vice President and Chief Financial Officer
M13003

Part II, Section A.2 and A.3 – Industrial Sites Con trolled by Submitter Occupational Exposure and Environmental Release and Disposal Page 1 of 1



## CONFIDENTIAL INFORMATION REMOVED
# C_2018319EN.01001601.xml

| 10.9.2018 | EN | Official Journal of the European Union | C 319/16 |
| --- | --- | --- | --- |

10.9.2018

EN

Official Journal of the European Union

C 319/16

---

Action brought on 20 June 2018 — Colombani v EEAS

(Case T-372/18)

(2018/C 319/19)

Language of the case: French

Parties

Applicant: Jean-Marc Colombani (Brussels, Belgium) (represented by N. de Montigny, lawyer)

Defendant: European External Action Service.

Form of order sought

The applicant claims that the Court should:

| — | annul the decision of the EEAS Director General for Budget and Administration of 9 November 2017 (ADMIN(2017)21) establishing the list of officials promoted in the 2017 promotion exercise in so far as it does not contain the applicant’s name; |
| --- | --- |

—

annul the decision of the EEAS Director General for Budget and Administration of 9 November 2017 (ADMIN(2017)21) establishing the list of officials promoted in the 2017 promotion exercise in so far as it does not contain the applicant’s name;

| — | order the defendant to pay the costs. |
| --- | --- |

—

order the defendant to pay the costs.

Pleas in law and main arguments

In support of the action, the applicant relies on four pleas in law.

| 1. | First plea in law, alleging illegality in respect of the general implementing provisions applied by the EEAS to the promotion procedure |
| --- | --- |

1.

First plea in law, alleging illegality in respect of the general implementing provisions applied by the EEAS to the promotion procedure

| 2. | Second plea in law, alleging maladministration, failure to comply with the procedure prior to the adoption of the list of officials proposed for promotion and unequal treatment. |
| --- | --- |

2.

Second plea in law, alleging maladministration, failure to comply with the procedure prior to the adoption of the list of officials proposed for promotion and unequal treatment.

| 3. | Third plea in law, alleging infringement of the general implementing provisions of the EEAS relating to Article 45 of the Staff Regulations. |
| --- | --- |

3.

Third plea in law, alleging infringement of the general implementing provisions of the EEAS relating to Article 45 of the Staff Regulations.

| 4. | Fourth plea in law, alleging a manifest error of assessment of the applicant’s merits and unequal treatment in the assessment of the seniority criterion. |
| --- | --- |

4.

Fourth plea in law, alleging a manifest error of assessment of the applicant’s merits and unequal treatment in the assessment of the seniority criterion.

---
EXHIBIT 10.2


 













EXTENSION AGREEMENT


EXTENSION AGREEMENT dated as of December 6, 2016 between Strata Skin Sciences, Inc. (the "Company"), a Delaware corporation, and Samuel E. Navarro (the "Consultant") effective as of January 1, 2017 (the "Effective Date").


Recitals:


The parties entered into a Consulting Agreement dated as of November 4, 2015, which was amended as of July 20, 2016 and September 19, 2016, (the "Agreement"), under which the Consultant provided consulting services to the Company.  The Agreement currently continues in effect through December 31, 2016.  The parties wish to extend the term of the Agreement through June 30, 2017, as provided in this Amendment.


NOW, THEREFORE, in consideration of the premises and covenants set forth herein, and intending to be legally bound hereby, the parties agree as follows:


1.          Section 3 of the Agreement is hereby amended to extend the termination date of the Agreement to June 30, 2017.


2.          Promptly after the date of this Amendment the Consultant will work with the President and Chief Executive Officer of the Company to establish the specific duties and objectives to be undertaken by the Consultant during the remaining term of the Agreement, which shall be communicated by the Chair of the Nominating and Governance Committee for review and approval.


3.          The parties acknowledge and agree that all of the terms, provisions, covenants and conditions of the Agreement shall hereafter continue in full force and effect in accordance with their terms, except to the extent amended, modified or revised herein.


IN WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the date first written above.







STRATA SKIN SCIENCES, INC.

















By: /s/ David K. Stone                                                  /s/ Samuel Navarro


David K. Stone, Chair                                           Samuel E. Navarro


Nominating and Governance Committee
December 29, 2003

22610

#### Casino v. State, Dept. of Health

Affirmed
IV 

114TH CONGRESS 

1ST SESSION H. RES. 185 

Amending the Rules of the House of Representatives to provide for the 

consideration of reported bills or joint resolutions that have not been 

considered by the House within 60 calendar days. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 26, 2015 

Mr. PETERS (for himself and Mr. MARINO) submitted the following resolution; 

which was referred to the Committee on Rules 

RESOLUTION 

Amending the Rules of the House of Representatives to 

provide for the consideration of reported bills or joint 

resolutions that have not been considered by the House 

within 60 calendar days. 

1 Resolved, 

2 SECTION 1. CONSIDERATION. 

3 Rule XIV of the Rules of the House of Representa4 tives is amended by adding at the end the following new 

5 clause: 

6 ‘‘7. If a bill or joint resolution reported by a com7 mittee has not been considered within 60 calendar days, 

8 the chair and ranking minority member of that committee, 


SSpencer on DSK4SPTVN1PROD with BILLS
2 

•HRES 185 IH 

1 or the chair and ranking minority member of the applica2 ble subcommittee of that committee may jointly offer a 

3 motion under clause 4 or 5, as applicable, for the consider4 ation of such bill or joint resolution.’’. 

5 SEC. 2. EFFECTIVE DATE. 

6 The amendment made by section 1 shall apply to bills 

7 or joint resolutions reported by any committee after the 

8 date of adoption of this resolution. 

Æ 


SSpencer on DSK4SPTVN1PROD with BILLS
24069

#### State v. Ferreira

Affirmed
#### State v. Pa

19089

5/27/97

Affirmed
[Federal Register Volume 88, Number 239 (Thursday, December 14, 2023)]
[Rules and Regulations]
[Page 86580]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-27506]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 161, 164, 184, and 186

[Docket No. FDA-2019-N-4750]
RIN 0910-AI15


Revocation of Uses of Partially Hydrogenated Oils in Foods; 
Confirmation of Effective Date

AGENCY: Food and Drug Administration, HHS.

ACTION: Direct final rule; confirmation of effective date.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or we) is confirming the 
effective date of December 22, 2023, for the final rule that appeared 
in the Federal Register of August 9, 2023. The direct final rule amends 
our regulations to no longer provide for the use of partially 
hydrogenated oils (PHOs) in food given our determination that PHOs are 
no longer generally recognized as safe (GRAS). The rule also revokes 
prior sanctions (i.e., pre-1958 authorization of certain uses) for the 
use of PHOs in margarine, shortening, and bread, rolls, and buns based 
on our conclusion that these uses of PHOs may be injurious to health. 
This document confirms the effective date of the direct final rule.

DATES: The effective date of December 22, 2023, for the direct final 
rule published in the Federal Register of August 9, 2023 (88 FR 53764) 
is confirmed.

FOR FURTHER INFORMATION CONTACT: Ellen Anderson, Center for Food Safety 
and Applied Nutrition, Office of Food Additive Safety (HFS-225), Food 
and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-
402-2378 or Keronica Richardson, Center for Food Safety and Applied 
Nutrition, Office of Regulations and Policy (HFS-024), Food and Drug 
Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-2378.

SUPPLEMENTARY INFORMATION: In the Federal Register of August 9, 2023 
(88 FR 53764), FDA issued a direct final rule amending its regulations 
that provide for the use of PHOs given our determination that PHOs are 
no longer GRAS and revoking prior sanctions (i.e., pre-1958 
authorization of certain uses) for the use of PHOs in margarine, 
shortening, and bread, rolls, and buns based on our conclusion that 
these uses of PHOs may be injurious to health. The direct final rule 
provided a 75-day comment period ending October 23, 2023. We stated 
that the effective date of the direct final rule would be on December 
22, 2023, 60 days after the end of the comment period, unless any 
significant adverse comment was submitted to FDA during the comment 
period. We did not receive any significant adverse comments.

    Authority: 21 U.S.C. 321, 341, 342, 343, 348, 371, 379e. 
Accordingly, the amendments issued thereby are effective on December 
22, 2023.

    Dated: December 11, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-27506 Filed 12-13-23; 8:45 am]
BILLING CODE 4164-01-P
# C_2019139EN.01005001.xml

| 15.4.2019 | EN | Official Journal of the European Union | C 139/50 |
| --- | --- | --- | --- |

15.4.2019

EN

Official Journal of the European Union

C 139/50

---

Judgment of the General Court of 28 February 2019 — Pozza v Parliament

(Case T-216/18) (1)

(Civil service - Officials - Remuneration - Expatriation allowance - Article 4(1)(a) of Annex VII to the Staff Regulations - Place where main activity is pursued - Inter-institutional transfer - Decision to no longer grant expatriation allowance - Competence - Legitimate expectations)

(2019/C 139/49)

Language of the case: French

Parties

Applicant: Geoffray Pozza (Waldbillig, Luxembourg) (represented by: S. Orlandi and T. Martin, lawyers)

Defendant: European Parliament (represented by: J. Van Pottelberge and M. Windisch, acting as Agents)

Re:

Application based on Article 270 TFEU seeking annulment of the decision of 8 June 2017 by which the Parliament no longer grants the applicant the expatriation allowance from the date on which he took up his duties.

Operative part of the judgment

The Court:

| 1. | Dismisses the action. |
| --- | --- |

1.

Dismisses the action.

| 2. | Orders Mr Geoffray Pozza to pay the costs. |
| --- | --- |

2.

Orders Mr Geoffray Pozza to pay the costs.

---

(1)  OJ C 211, 18.6.2018.

---